MedWatch

GSK to invest USD 1.2bn in infectious disease battle

The UK drugmaker has joined a string of pharmaceutical firms that are responding to a call of action concerning future drug resistance.

Photo: Daniel Karmann/AP/Ritzau Scanpix

GSK Plc plans to invest GBP 1bn (USD 1.2bn) over a decade to accelerate work on new medicines and vaccines to combat malaria, tuberculosis, HIV, neglected tropical diseases and antibiotic resistance.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs